Provided By PR Newswire
Last update: Jun 16, 2025
NEW YORK, June 16, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Sage Therapeutics, Inc. (NASDAQ: SAGE) and its board of directors concerning the proposed acquisition of the company by Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). Stockholders will receive $8.50 and once contingent value right worth up to $3.50 for each share of Sage Therapeutics, Inc. stock that they hold. The transaction is valued between $561 million and $795 million and is expected to close in the third quarter of 2025.
Read more at prnewswire.com9.11
-0.03 (-0.33%)
32.34
-1.25 (-3.72%)
Find more stocks in the Stock Screener